NovaBay Pharmaceuticals, Inc. (NBY): Price and Financial Metrics

NBY POWR Grades

• NBY scores best on the Sentiment dimension, with a Sentiment rank ahead of 71.38% of US stocks.
• The strongest trend for NBY is in Momentum, which has been heading down over the past 48 weeks.
• NBY ranks lowest in Stability; there it ranks in the 5th percentile.

NBY Stock Summary

• NBY has a market capitalization of $28,314,319 -- more than approximately merely 3.72% of US stocks.
• For NBY, its debt to operating expenses ratio is greater than that reported by just 6.95% of US equities we're observing.
• With a year-over-year growth in debt of -79.02%, NovaBay Pharmaceuticals Inc's debt growth rate surpasses just 3.82% of about US stocks.
• Stocks that are quantitatively similar to NBY, based on their financial statements, market capitalization, and price volatility, are MANT, PETS, UFPT, JVA, and ROCK.
• NBY's SEC filings can be seen here. And to visit NovaBay Pharmaceuticals Inc's official web site, go to www.novabay.com.

NBY Valuation Summary

• In comparison to the median Healthcare stock, NBY's EV/EBIT ratio is 108.19% lower, now standing at -2.4.
• NBY's EV/EBIT ratio has moved up 12.6 over the prior 169 months.
• NBY's price/sales ratio has moved down 13.3 over the prior 169 months.

Below are key valuation metrics over time for NBY.

NBY Growth Metrics

• The 5 year net income to common stockholders growth rate now stands at 59.04%.
• The 4 year price growth rate now stands at -57.65%.
• Its 2 year cash and equivalents growth rate is now at -31.53%.

NBY's revenue has moved down $7,201,000 over the prior 33 months.

The table below shows NBY's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-06-30	7.998	-6.221	-8.352
2021-03-31	9.849	-5.275	-10.975
2020-12-31	9.934	-4.721	-11.039
2020-09-30	9.75	-4.705	-12.8
2020-06-30	9.195	-4.835	-9.861
2020-03-31	7	-5.573	-7.88

NBY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• NBY has a Quality Grade of C, ranking ahead of 40.43% of graded US stocks.
• NBY's asset turnover comes in at 0.533 -- ranking 77th of 677 Pharmaceutical Products stocks.
• AMGN, AMRN, and UTHR are the stocks whose asset turnover ratios are most correlated with NBY.

The table below shows NBY's key quality metrics over time.